Kristen Scammon, a partner at Torres, Scammon & Day, was unanimously elected to TargetCancer’s Board of Directors. Her term begins April 1, 2014.
TargetCancer, Inc. is a non-profit organization that promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations, and raising awareness among scientists, clinicians, and patients.
Kristen first became involved in TargetCancer five years ago when the organization was founded by a remarkable friend and colleague after his diagnosis with a rare cancer. She recently served as a member of the 2013 Gala Event Committee, one of the organization’s primary fundraising events. When notified about her appointment to the Board, Kristen said, “It is a privilege and an honor to serve on TargetCancer’s Board especially during this time of progress and growth. I look forward to helping advance the organization’s mission.”
Kristen has more than 15 years of litigation experience. She represents individuals and businesses in white collar litigation and business disputes in federal and state trial courts in Massachusetts, the First Circuit Court of Appeals, as well as at mediations and arbitrations.